Polymyalgia rheumatica treatment is which of the following?

• A. Steroids (low-dose)
• B. NSAIDs alone
• C. Methotrexate
• D. Biologic therapy

Answer: (D)

Polymyalgia rheumatica involves systemic inflammation driven in part by interleukin-6 signaling, so therapies that directly block this inflammatory pathway can be highly effective and offer steroid-sparing benefits. Biologic therapy, particularly IL-6 inhibitors, provides targeted control of the inflammatory process, which can lead to rapid symptom relief and allow tapering or avoiding long-term glucocorticoids in patients where steroids pose risks or are not well tolerated. That targeted mechanism makes it the best choice among the options when considering disease control with a focus on reducing steroid exposure. In practice, low-dose steroids remain the standard first-line approach for most patients, while NSAIDs alone are insufficient and methotrexate may help some as an adjunct, but biologics offer a direct anti-inflammatory strategy that can be especially valuable in refractory or steroid-sparing scenarios.